Terms: = Kidney tumors AND PDGFB, SIS, 5155, ENSG00000100311, FLJ12858, PDGF2, P01127, c-sis, SSV
38 results:
1. Cancer Cell-Derived pdgfb Stimulates mTORC1 Activation in Renal Carcinoma.
Abuhamad AY; Mohamad Zamberi NN; Vanharanta S; Mohd Yusuf SNH; Mohtar MA; Syafruddin SE
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047421
[TBL] [Abstract] [Full Text] [Related]
2. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.
Bian Z; Fan R; Xie L
Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236
[TBL] [Abstract] [Full Text] [Related]
3. Stigma and related influencing factors in postoperative oral cancer patients in China: a cross-sectional study.
Tan C; Zhong C; Mei R; Yang R; Wang D; Deng X; Chen S; Ye M
Support Care Cancer; 2022 Jun; 30(6):5449-5458. PubMed ID: 35305161
[TBL] [Abstract] [Full Text] [Related]
4. BAI1 as a Prognostic Marker of Clear Cell Renal Cell Carcinoma (ccRCC).
Pesta M; Travnicek I; Kulda V; Windrichova J; Rezackova H; Houfkova K; Macanova T; Bendova B; Nestorova A; Hes O; Hora M; Topolcan O; Polivka J
Anticancer Res; 2021 Sep; 41(9):4463-4470. PubMed ID: 34475070
[TBL] [Abstract] [Full Text] [Related]
5. Gold Nanorods are Selective Cytotoxic Agents.
El Gendy M; Weinfeld M; Abdoon A
Anticancer Agents Med Chem; 2022; 22(5):991-998. PubMed ID: 34315395
[TBL] [Abstract] [Full Text] [Related]
6. Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes.
Henriksen JN; Bøttger P; Hermansen CK; Ladefoged SA; Nissen PH; Hamilton-Dutoit S; Fink TL; Donskov F
Clin Genitourin Cancer; 2020 Feb; 18(1):62-68.e2. PubMed ID: 31640912
[TBL] [Abstract] [Full Text] [Related]
7. A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma.
Syafruddin SE; Rodrigues P; Vojtasova E; Patel SA; Zaini MN; Burge J; Warren AY; Stewart GD; Eisen T; Bihary D; Samarajiwa SA; Vanharanta S
Nat Commun; 2019 Mar; 10(1):1152. PubMed ID: 30858363
[TBL] [Abstract] [Full Text] [Related]
8. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
[TBL] [Abstract] [Full Text] [Related]
9. Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models.
Hong B; Yang Y; Guo S; Duoerkun S; Deng X; Chen D; Yu S; Qian W; Li Q; Li Q; Gong K; Zhang N
Oncotarget; 2017 Jul; 8(30):49839-49850. PubMed ID: 28548943
[TBL] [Abstract] [Full Text] [Related]
10. Renal findings in patients with Mulibrey nanism.
Sivunen J; Karlberg S; Lohi J; Karlberg N; Lipsanen-Nyman M; Jalanko H
Pediatr Nephrol; 2017 Sep; 32(9):1531-1536. PubMed ID: 28432469
[TBL] [Abstract] [Full Text] [Related]
11. Clear cell renal cell carcinoma: identifying the gain of chromosome 12 on multiphasic MDCT.
Young JR; Coy H; Douek M; Lo P; Sayre J; Pantuck AJ; Raman SS
Abdom Radiol (NY); 2017 Jan; 42(1):236-241. PubMed ID: 27519835
[TBL] [Abstract] [Full Text] [Related]
12. Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
Ma X; Wang L; Li H; Zhang Y; Gao Y; Guo G; Liu K; Meng Q; Zhao C; Wang D; Song Z; Zhang X
Sci Rep; 2016 Aug; 6():30886. PubMed ID: 27488093
[TBL] [Abstract] [Full Text] [Related]
13. Expression of neural cell adhesion molecule L1 (CD171) in neuroectodermal and other tumors: An immunohistochemical study of 5155 tumors and critical evaluation of CD171 prognostic value in gastrointestinal stromal tumors.
Inaguma S; Wang Z; Lasota JP; Miettinen MM
Oncotarget; 2016 Aug; 7(34):55276-55289. PubMed ID: 27419370
[TBL] [Abstract] [Full Text] [Related]
14. The Involvement of PDGF-B/PDGFRβ Axis in the Resistance to Antiangiogenic and Antivascular Therapy in Renal Cancer.
Cumpănas AA; Cimpean AM; Ferician O; Ceausu RA; Sarb S; Barbos V; Dema A; Raica M
Anticancer Res; 2016 May; 36(5):2291-5. PubMed ID: 27127135
[TBL] [Abstract] [Full Text] [Related]
15. Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide.
Cates CC; Arias AD; Nakayama Wong LS; Lamé MW; Sidorov M; Cayanan G; Rowland DJ; Fung J; Karpel-Massler G; Siegelin MD; Greene LA; Angelastro JM
Oncotarget; 2016 Mar; 7(11):12718-30. PubMed ID: 26863637
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma.
Shim M; Song C; Park S; Choi SK; Cho YM; Kim CS; Ahn H
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2213-20. PubMed ID: 26215891
[TBL] [Abstract] [Full Text] [Related]
17. Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma.
Chang Y; An H; Xu L; Zhu Y; Yang Y; Lin Z; Xu J
Br J Cancer; 2015 Aug; 113(4):626-33. PubMed ID: 26135896
[TBL] [Abstract] [Full Text] [Related]
18. [Effect of platelet derived growth factor-B and its receptor expression on the proliferation of renal cell carcinoma ACHN cells].
Wang W; Zhang Z; Wang S; Du J; Yao X
Zhonghua Zhong Liu Za Zhi; 2015 Mar; 37(3):170-4. PubMed ID: 25975783
[TBL] [Abstract] [Full Text] [Related]
19. Effect of platelet-derived growth factor-B on renal cell carcinoma growth and progression.
Wang W; Qi L; Tan M; Zhang Z; Du J; Wei X; Yao X
Urol Oncol; 2015 Apr; 33(4):168.e17-27. PubMed ID: 25766258
[TBL] [Abstract] [Full Text] [Related]
20. VEGF/VEGFR2 and PDGF-B/PDGFR-β expression in non-metastatic renal cell carcinoma: a retrospective study in 1,091 consecutive patients.
Song SH; Jeong IG; You D; Hong JH; Hong B; Song C; Jung WY; Cho YM; Ahn H; Kim CS
Int J Clin Exp Pathol; 2014; 7(11):7681-9. PubMed ID: 25550804
[TBL] [Abstract] [Full Text] [Related]
[Next]
